The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
about
Gene therapy for carcinoma of the breast: Genetic ablation strategiesCorrelation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor statusRole of DUSP1/MKP1 in tumorigenesis, tumor progression and therapyScribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary glandQuantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry.S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisIn Utero exposure to low-dose alcohol induces reprogramming of mammary development and tumor risk in MMTV-erbB-2 transgenic miceA Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA PloidyDevelopment of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.Critical determination of the frequency of c-erbB-2 amplification in breast cancer.miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breastElevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrenceDominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomasThe role of Herceptin in early breast cancerGenetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Identification of p130Cas/ErbB2-dependent invasive signatures in transformed mammary epithelial cells.Biological indices in the assessment of breast cancer.ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2+ breast cancer patients and is critical for tumorigenesis in HER2+ breast cancer cells.Absence of activating mutations in the transmembrane domain of the c-erbB-2 protooncogene in human lung cancer.p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.Analysis of oncogenes and tumor suppressor genes in human breast cancer.
P2860
Q24797953-B780DF6E-1698-47B2-BC5B-3E9F43801338Q24806597-277CB1BD-6718-4430-9A6C-A5874ECECFCCQ26745758-BC2626D5-B24F-49E1-A9D2-935DC1B0B685Q27315980-5BB52980-408E-4BFA-B472-7D27B094BE9CQ28360826-CC64A175-948C-4EF3-BFF7-BE8C458BF614Q33322536-5A7A5A7F-C2B9-470E-AB56-1A152B1EC654Q34493341-E8A4E85B-0996-4C22-BBFC-D19420136D86Q35585536-FA6DD151-8B1F-45DE-B39A-CAD25227093AQ35684433-EE21DE80-DA5B-4A5F-BFA2-9B5FCF9A1FBCQ35787289-B81D7C03-66B9-46CC-871F-B33E81B5C8E9Q36079541-6238C988-A0BD-4F7F-9207-DE8B49BF52EFQ36132797-16888D5B-4371-4003-AE3C-28F45F739E1FQ36134576-824CB3D9-BB4D-48B6-B4BD-3530C774249CQ36438653-8C24162F-3273-4024-B3AF-5EE2D77E182CQ36623838-8C28178E-2FCC-4760-8186-D35100CDB755Q36644476-B58732AE-8226-4DCF-B8BE-CAFF30734398Q36657407-57353878-9B70-445D-B697-4892D931BB1CQ37101367-0F963AB4-81E1-43F1-8119-B51B263AE2B8Q37326072-727B8F27-83EA-4AD5-9346-9EF4DCCB0844Q37344798-64BC7033-1BFA-42D6-B5E0-731948ABD8BAQ40848953-4FD52E6C-1C19-4649-9DFF-F91C264F9A1CQ42378364-5F5E3408-71B5-471F-ABA7-E20CA085E73DQ54970999-210A38D1-4A0A-4DD4-82FD-5C9DAB4E2356Q55235050-965C39B4-5E30-4477-AE71-D94D50727C86Q55387322-862D276C-4FFA-4C6C-A1E7-FAC04436D23C
P2860
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
@en
type
label
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
@en
prefLabel
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
@en
P2093
P1433
P1476
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
@en
P2093
P304
P407
P577
1992-05-01T00:00:00Z